• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $STIM

    Neuronetics Inc.

    Subscribe to $STIM
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.

    IPO Year: 2018

    Exchange: NASDAQ

    Website: neurostar.com

    Peers

    $BWAY
    $GBNH

    Recent Analyst Ratings for Neuronetics Inc.

    DatePrice TargetRatingAnalyst
    8/13/2024Outperform → Mkt Perform
    William Blair
    10/14/2021$18.00 → $12.00Market Outperform
    JMP Securities
    10/13/2021Outperform → Mkt Perform
    William Blair
    10/13/2021Buy → Neutral
    BTIG
    See more ratings

    Neuronetics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month

      New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sharing patient and provider stories that highlight the impact NeuroStar has as a safe, effective, and non-drug treatment for depression MALVERN, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, is proud to launch the first National TMS Therapy Awareness Day. The event will take

      5/14/25 8:31:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Reports First Quarter 2025 Financial and Operating Results

      MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2025. First Quarter 2025 Highlights First quarter 2025 revenue of $32.0 million, an 84% increase as compared to the first quarter 2024, primarily driven by the Greenbrook acquisitionU.S. clinic revenue of $18.7 million in the quarter representing Greenbrook clinic re

      5/6/25 7:10:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      MALVERN, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 4,500 shares of the Company's common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company. The RSU grants vest ratably in equal insta

      5/5/25 4:30:00 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

      MALVERN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2025 financial and operating results prior to market open on Tuesday, May 6, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/knieqjnc. To listen to the conference call on your telephone, participants may register for the

      4/22/25 8:30:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression

      MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, announced that Evernorth Health Services, a wholly owned subsidiary of The Cigna Group, has expanded its coverage of NeuroStar® Transcranial Magnetic Stimulation (TMS) to include adolescents aged 15 and older living with major depressive disorder (MDD). As these health policies cover 15 million lives, the expansion greatly improves access to non-drug treatment options for ado

      3/31/25 8:31:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results

      MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") is issuing this press release to update the reporting of its financial results for the fourth quarter and full year ending December 31, 2024. Following the Company's press release on March 4, 2025 initially issuing the Company's fourth quarter and full year 2024 financial results (the "Initial Release") and in connection with finalizing the audited financial statements for the fiscal year ending December 31, 2024, certain non-cash revisions were made to the financial statements related to the Company's acquisition of Greenbrook TMS Inc. ("Greenbrook") and the shares outstanding

      3/27/25 4:30:00 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

      MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Acquired Greenbrook TMS on December 9, 2024Received an incremental $10 million in funding from Perceptive AdvisorsFourth quarter 2024 revenue of $22.5 million, a 11% increase as compared to the fourth quarter 2023U

      3/4/25 7:10:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 24,750 shares of the Company's common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company. Three of the RSU grants vests ratably i

      3/3/25 4:30:00 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call

      MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/a3eb5opb. To listen to the conference call on your telephone, participants may register fo

      2/21/25 8:30:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 15,750 shares of the Company's common stock (RSUs) to two new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company. Each of the RSU grants vests ratably in eq

      2/7/25 4:30:00 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    Neuronetics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Neuronetics Inc.

      10-Q - Neuronetics, Inc. (0001227636) (Filer)

      5/6/25 7:30:47 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - Neuronetics, Inc. (0001227636) (Filer)

      5/6/25 7:10:26 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Neuronetics Inc.

      DEFA14A - Neuronetics, Inc. (0001227636) (Filer)

      4/10/25 4:33:49 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Neuronetics Inc.

      DEF 14A - Neuronetics, Inc. (0001227636) (Filer)

      4/10/25 4:32:07 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Neuronetics Inc.

      10-K - Neuronetics, Inc. (0001227636) (Filer)

      3/27/25 4:36:09 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form PRE 14A filed by Neuronetics Inc.

      PRE 14A - Neuronetics, Inc. (0001227636) (Filer)

      3/27/25 4:35:45 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: Neuronetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Completion of Acquisition or Disposition of Assets

      8-K/A - Neuronetics, Inc. (0001227636) (Filer)

      3/27/25 4:35:12 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - Neuronetics, Inc. (0001227636) (Filer)

      3/4/25 7:00:54 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Neuronetics Inc.

      144 - Neuronetics, Inc. (0001227636) (Subject)

      2/19/25 3:16:15 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B5 filed by Neuronetics Inc.

      424B5 - Neuronetics, Inc. (0001227636) (Filer)

      2/10/25 6:03:18 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    Neuronetics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Neuronetics Inc.

      SC 13D - Neuronetics, Inc. (0001227636) (Subject)

      12/17/24 9:15:11 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

      SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

      11/14/24 1:42:23 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

      SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

      11/14/24 11:17:47 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

      SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

      8/14/24 6:17:37 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Neuronetics Inc.

      SC 13G - Neuronetics, Inc. (0001227636) (Subject)

      6/28/24 3:04:39 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Neuronetics Inc.

      SC 13G - Neuronetics, Inc. (0001227636) (Subject)

      4/1/24 5:30:16 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Neuronetics Inc. (Amendment)

      SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

      2/14/24 11:46:59 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Neuronetics Inc. (Amendment)

      SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

      2/14/24 10:21:36 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Neuronetics Inc. (Amendment)

      SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

      2/13/24 11:10:24 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Neuronetics Inc.

      SC 13G - Neuronetics, Inc. (0001227636) (Subject)

      9/22/23 4:14:53 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    Neuronetics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cascella Robert bought $75,000 worth of shares (100,000 units at $0.75), increasing direct ownership by 28% to 453,098 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      9/13/24 5:02:03 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Muir Glenn P bought $20,000 worth of shares (25,000 units at $0.80), increasing direct ownership by 9% to 289,818 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      9/6/24 5:05:03 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Muir Glenn P bought $21,250 worth of shares (25,000 units at $0.85), increasing direct ownership by 10% to 264,818 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      8/30/24 5:15:02 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Muir Glenn P bought $25,000 worth of shares (25,000 units at $1.00), increasing direct ownership by 12% to 239,818 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      8/21/24 5:15:02 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Cascella Robert bought $41,660 worth of shares (39,000 units at $1.07), increasing direct ownership by 12% to 353,098 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      8/19/24 5:13:15 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Cascella Robert bought $58,450 worth of shares (70,000 units at $0.83), increasing direct ownership by 29% to 314,098 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      8/16/24 5:15:05 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Muir Glenn P bought $18,878 worth of shares (25,171 units at $0.75), increasing direct ownership by 13% to 214,818 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      8/16/24 5:15:04 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Cascella Robert bought $102,550 worth of shares (50,000 units at $2.05), increasing direct ownership by 26% to 244,098 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      6/6/24 5:15:03 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Cascella Robert bought $51,670 worth of shares (28,500 units at $1.81), increasing direct ownership by 21% to 162,848 units (Amendment)

      4/A - Neuronetics, Inc. (0001227636) (Issuer)

      9/20/23 6:15:04 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    Neuronetics Inc. Financials

    Live finance-specific insights

    See more

    Neuronetics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    Neuronetics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

      MALVERN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2025 financial and operating results prior to market open on Tuesday, May 6, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/knieqjnc. To listen to the conference call on your telephone, participants may register for the

      4/22/25 8:30:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call

      MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/a3eb5opb. To listen to the conference call on your telephone, participants may register fo

      2/21/25 8:30:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results

      MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Neuronetics, Inc. (NASDAQ:STIM), please note that in the second paragraph of the "Stockholders Approve Acquisition of Greenbrook TMS" section, it should say that the Company expects to achieve cash flow breakeven by the third quarter of 2025, not the second. The corrected release follows: Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and ope

      11/12/24 6:45:48 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results

      MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2024. Third Quarter 2024 Highlights Third quarter 2024 revenue of $18.5 million, a 4% increase as compared to the third quarter 2023U.S. NeuroStar Advanced Therapy system revenue of $4.1 million in the quarter, representing 48 systemsU.S. treatment session revenue increased by 2% versus the third quarter of

      11/12/24 7:10:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call

      MALVERN, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release third quarter 2024 financial and operating results prior to market open on Tuesday, November 12, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/yk5bidgv. To listen to the conference call on your telephone, participants may register for

      10/29/24 4:30:00 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge

      MALVERN, Pa. and TORONTO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTC:GBNHF) ("Greenbrook") today announced that they have entered into a definitive arrangement agreement (the "Definitive Agreement") in which Neuronetics will acquire all of the outstanding common shares of Greenbrook in an all-stock transaction. "This transaction brings together two of the leaders in the mental health space in the U.S., which will allow us to provide access to innovative care to patients suffering from mental health conditions. Leveraging the significant scale and capabilities of the two businesses, we can drive increased awareness of Neur

      8/12/24 7:15:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Reports Record Second Quarter 2024 Financial and Operating Results

      MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the second quarter of 2024. Second Quarter 2024 Highlights Second quarter 2024 revenue of $16.5 million, a 7% decrease as compared to the second quarter 2023U.S. NeuroStar Advanced Therapy system revenue of $4 million in the quarter, representing 50 systemsU.S. treatment session revenue decreased by 5% ve

      8/12/24 7:10:54 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call

      MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2024 financial and operating results prior to market open on Monday, August 12th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/xsxbsaxh. To listen to the conference call on your telephone, participants may register f

      7/29/24 8:30:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Reports Record First Quarter 2024 Financial and Operating Results

      MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2024. First Quarter 2024 Highlights First quarter 2024 revenue of $17.4 million, a 12% increase as compared to the first quarter 2023U.S. treatment session revenue increased by 22% versus the first quarter of 2023U.S. NeuroStar Advanced Therapy system revenue of $3.3 million, in the quarter; the Company s

      5/7/24 7:30:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call

      MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2024 financial and operating results prior to market open on Tuesday, May 7th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/i3t5h9gs. To listen to the conference call on your telephone, participants may register for the

      4/23/24 4:30:00 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • EVP, CFO and Treasurer Furlong Stephen sold $853,281 worth of shares (200,000 units at $4.27), decreasing direct ownership by 33% to 410,053 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/14/25 5:05:11 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 4 filed by President and CEO Sullivan Keith J

      4/A - Neuronetics, Inc. (0001227636) (Issuer)

      3/13/25 5:30:13 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 4 filed by EVP, CFO and Treasurer Furlong Stephen

      4/A - Neuronetics, Inc. (0001227636) (Issuer)

      3/13/25 5:28:03 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 4 filed by EVP, GC, CCO and CS Macan William Andrew

      4/A - Neuronetics, Inc. (0001227636) (Issuer)

      3/13/25 5:24:31 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • EVP, GC, CCO and CS Macan William Andrew sold $1,689 worth of shares (377 units at $4.48), decreasing direct ownership by 0.07% to 526,805 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      3/6/25 5:00:04 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • EVP, CFO and Treasurer Furlong Stephen sold $8,364 worth of shares (1,867 units at $4.48), decreasing direct ownership by 0.31% to 610,053 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      3/6/25 5:00:06 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • President and CEO Sullivan Keith J was granted 375,000 shares, increasing direct ownership by 30% to 1,607,988 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      2/26/25 5:49:57 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • EVP, GC, CCO and CS Macan William Andrew was granted 157,500 shares, increasing direct ownership by 43% to 527,182 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      2/26/25 5:48:24 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • EVP, CFO and Treasurer Furlong Stephen was granted 157,500 shares, increasing direct ownership by 35% to 611,920 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      2/26/25 5:46:58 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • President and CEO Sullivan Keith J sold $229,237 worth of shares (50,374 units at $4.55), decreasing direct ownership by 4% to 1,232,988 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      2/20/25 5:21:02 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics downgraded by William Blair

      William Blair downgraded Neuronetics from Outperform to Mkt Perform

      8/13/24 10:26:16 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • JMP Securities reiterated coverage on Neuronetics with a new price target

      JMP Securities reiterated coverage of Neuronetics with a rating of Market Outperform and set a new price target of $12.00 from $18.00 previously

      10/14/21 8:41:45 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics downgraded by William Blair

      William Blair downgraded Neuronetics from Outperform to Mkt Perform

      10/13/21 12:25:53 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics downgraded by BTIG

      BTIG downgraded Neuronetics from Buy to Neutral

      10/13/21 6:18:03 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Piper Sandler reiterated coverage on Neuronetics with a new price target

      Piper Sandler reiterated coverage of Neuronetics with a rating of Overweight and set a new price target of $25.00 from $27.00 previously

      3/2/21 12:02:41 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics upgraded by William Blair

      William Blair upgraded Neuronetics from Market Perform to Outperform

      1/22/21 7:39:34 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    Neuronetics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

      Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

      7/12/23 9:00:00 AM ET
      $STIM
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors

      MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced the appointment of Joseph H. Capper to its Board of Directors and as a member of the Audit Committee effective January 1, 2023. "Joe is well known and extremely well regarded in the med-tech community for his ability to advance company goals," said Rob Cascella, Chairman of the Board of Neuronetics. "His depth of experience with public companies and his passion for innovative medical technologies will

      12/29/22 4:29:00 PM ET
      $BEAT
      $STIM
      Medical/Dental Instruments
      Health Care
    • IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

      MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

      11/11/21 7:26:31 PM ET
      $BEAT
      $GMED
      $GTHX
      $HOLX
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Electronics
    • Anika Appoints Sheryl Conley to Board of Directors

      BEDFORD, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that its Board of Directors has appointed Sheryl Conley as independent director, effective October 28, 2021. Sheryl Conley joins the Anika Board of Directors with over 35 years of orthopedic and healthcare industry experience, most recently as President and CEO of OrthoWorx, Inc., and previously as Group President, Americas and Global Brand Management, and Chief Marketing Officer for Zimmer, Inc. Ms. Conley brings extensive orthopedic medical device industry knowledge with a focus on global brand management

      11/1/21 9:00:00 AM ET
      $ANIK
      $SRGA
      $STIM
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Neuronetics Announces Appointment of Megan Rosengarten to its Board of Directors

      MALVERN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the appointment of Megan Rosengarten as a new member of its Board of Directors. Following her appointment, the Neuronetics' Board of Directors now has eight members."I am very pleased to have Megan join Neuronetics' Board of Directors," said Keith Sullivan, President and Chief Executive Officer of Neuronetics, Inc. "Her background in medical technology product development, marketing, and strategic communicatio

      8/5/21 4:30:00 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Announces Retirement of Brian Farley and Appointment of Robert Cascella as Chairman of its Board of Directors

      MALVERN, Pa., April 14, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Brian Farley will retire from the Neuronetics' Board of Directors and his role as Chairman following the company's Annual Meeting of Stockholders on May 27, 2021. Robert Cascella, who joined the Board of Directors on April 1, 2021, will be appointed as Chairman of its Board of Directors following Mr. Farley's retirement. Following Mr. Farley's retirement, the Board of Directors will have seven members. "

      4/14/21 5:15:14 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Announces Appointment of Robert Cascella to its Board of Directors

      MALVERN, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the appointment of Robert A. Cascella to its Board of Directors, effective immediately. Following his appointment, the Neuronetics’ Board of Directors now has eight members. “I am very pleased to have a leader of Rob’s quality and experience join Neuronetics’ Board of Directors,” said Keith Sullivan, President and Chief Executive Officer of Neuronetics, Inc. “His history of value creation in healthcare uniq

      4/1/21 4:05:00 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Announces Retirement of Gregory Harper, Vice President, R&D and Clinical

      MALVERN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Gregory Harper, the company’s Vice President, R&D and Clinical, will retire effective March 31, 2021. “I am grateful to Greg for his outstanding leadership of Neuronetics’ product development function over the past five years and more recently clinical affairs. Greg has made enormous contributions to our organization,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics, Inc. “

      3/11/21 4:25:08 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Announces Expansion of Sales Organization

      MALVERN, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the expansion of its commercial organization. Sales Organization UpdateAs part of the Company’s previously announced sales organization optimization initiative, the Company recently expanded the size of its sales organization, including the addition of: Thirteen new Business Development Managers (“BDMs”), bringing the total number of BDMs to 22Nine new NeuroStar Practice Consultants (“NPCs”), bringing the to

      1/7/21 8:00:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care